Tempus AI (TEM): Navigating Volatility After Strong Q1 Growth and Strategic Moves
Key Takeaways
- Tempus AI reported Q1 2026 revenue growth of 36% year-over-year to $348.1 million, driven by diagnostics and data applications.
- Company raised full-year 2026 revenue guidance to $1.59–$1.60 billion, targeting ~$65 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
- Recent collaborations with Bristol Myers Squibb and Lucent Diagnostics expand AI applications in oncology and Alzheimer’s testing.
- Upsized $400 million convertible senior notes offering to optimize capital structure and reduce debt costs.
- Stock has traded within a 52-week range of $41.73–$104.32 amid volatile price action in recent weeks.
- Analyst consensus leans "Buy" with average price targets around $69, implying potential upside.
Current Market Snapshot for TEM
I've been keeping a close eye on Tempus AI (TEM) as it moves through some choppy trading sessions, much like other AI-driven healthcare stocks. The shares have retreated from highs near $104, stabilizing around the $42–$46 range with elevated volumes. From what I see, this pullback comes despite solid fundamentals—strong revenue growth and key partnerships—offset by capital raises and the losses common in growth-stage tech companies. Investor sentiment seems to weigh the promise of AI in precision medicine against questions about profitability timelines and rotations out of high-valuation names. With institutions like ARK Invest active, this feels like a potential turning point in the market cycle.
Recent Developments Shaping TEM's Trajectory
Tempus AI, at the forefront of AI-powered precision medicine, has had its share price swayed by a flurry of updates lately. On May 5, they delivered Q1 2026 results with revenue hitting $348.1 million, a 36.1% year-over-year increase that beat expectations. Diagnostics revenue climbed 34.7% to $261.1 million, powered by oncology testing volumes in solid tumors, liquid biopsies, and minimal residual disease (MRD) assays. Meanwhile, Data & Applications jumped 40.5% to $87.0 million, thanks to licensing and demand for AI tools. Gross profit rose 43.1% to $222.0 million, even as the net loss expanded to $125.9 million from investments; the adjusted EBITDA loss improved to $2.8 million. Management lifted full-year 2026 revenue guidance to $1.59–$1.60 billion (about 25% growth) and ~$65 million in adjusted EBITDA, pointing to momentum from the Merck collaboration and operating leverage.
The initial beat lifted shares, but volatility set in as margins in the guidance raised some eyebrows. Stocks dipped 4-7% in follow-up sessions on profit-taking. Then, on May 7, Tempus announced a proposed $350 million (upsized to $400 million by May 8) 0% convertible senior notes due 2032 offering, which should net ~$384 million. Proceeds will repay $307.7 million in senior secured loans, lower interest costs, fund capped calls to curb dilution, and cover general needs. This strengthens liquidity to $643.8 million but sparked dilution worries, leading to a ~7.5% drop that day.
Strategic moves have helped offset some downside. On May 6, a partnership with Lucent Diagnostics brings blood-based Alzheimer’s biomarker testing (LucentAD Complete) into Tempus workflows, extending beyond oncology. They also launched a new AI effort with Bristol Myers Squibb (BMY), using multimodal real-world data to optimize oncology clinical trials. Analysts offered mixed updates: BTIG lowered its target to $80 from $90 (Buy), HC Wainwright to $64 from $95 (Buy), Baird to $59 from $68, but TD Cowen upped to $68. Consensus remains "Buy" around $69. ARK Invest added shares on May 7 and 11, showing confidence. In my view, the strong fundamentals are clashing with financing concerns and sector shifts, resulting in ~14% weekly declines from $53+ peaks, with volumes 2-3x average highlighting changing convictions.
Exploring AI Trading Bots for Insights
One tool I rely on for deeper analysis is Tickeron’s Trending AI Robots page, which highlights top-performing AI trading bots from hundreds available. These bots trade thousands of tickers using strategies like swing trading, momentum, mean reversion, and trend following, often showing win rates of 60-80%, backtested annual returns of 15-50%, and Sharpe ratios over 1.5. Only the most adaptable ones, especially those with AI pattern recognition for volatile sectors like healthcare, make the list. I find it useful to filter for bots suited to tech or healthcare, focusing on max drawdowns under 20% or profit factors above 1.8. Checking this page helps me evaluate options that could complement a portfolio like one holding TEM, keeping pace with market shifts.
2026 Outlook and What I'm Watching
Looking ahead in 2026, execution on the raised revenue guidance will be key as AI adoption grows in healthcare. Growth should come from diagnostics in oncology and areas like Alzheimer’s, plus data licensing from pharma ties such as Merck and BMS. AI efficiencies might drive operating leverage toward adjusted EBITDA positivity, but maintaining gross margins depends on scaling volumes and controlling R&D and sales costs.
This is important because risks like regulatory oversight on AI diagnostics, reimbursement for molecular tests, and competition from players like Illumina or Guardant Health in precision oncology loom large. Broader factors—healthcare spending, biotech funding—will play a role too. On the upside, AI tools for clinical trials and real-world evidence datasets could speed pharma development. Tempus's edge lies in its proprietary multimodal data and Chicago hub, though post-notes debt service and cash burn need monitoring. I also checked this using Tickeron’s AI Screener to gauge how TEM stacks up against industry peers. Ultimately, quarterly results, partnership progress, and the path to GAAP profitability will define the story.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for TEM shows an upward move is likely
TEM's Aroon Indicator triggered a bullish signal on June 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 50 similar instances where the Aroon Indicator showed a similar pattern. In of the 50 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on TEM as a result. In of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TEM just turned positive on June 24, 2026. Looking at past instances where TEM's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .
TEM moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TEM crossed bullishly above the 50-day moving average on June 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in of 111 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on July 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TEM broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (24.691) is slightly higher than the industry average of (7.366). P/E Ratio (39.298) is within average values for comparable stocks, (50.081). TEM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.153). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (7.402) is also within normal values, averaging (5.651).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement